NCT06854341View on ClinicalTrials.gov

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

CompletedOBSERVATIONAL
Enrollment

5,448

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions
Multiple Sclerosis, Relapsing-Remitting
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY